Literature DB >> 23321250

SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma.

Maria Carmela Vegliante1, Jara Palomero, Patricia Pérez-Galán, Gaël Roué, Giancarlo Castellano, Alba Navarro, Guillem Clot, Alexandra Moros, Helena Suárez-Cisneros, Sílvia Beà, Luis Hernández, Anna Enjuanes, Pedro Jares, Neus Villamor, Dolors Colomer, José Ignacio Martín-Subero, Elias Campo, Virginia Amador.   

Abstract

Mantle cell lymphoma (MCL) is one of the most aggressive lymphoid neoplasms whose pathogenesis is not fully understood. The neural transcription factor SOX11 is overexpressed in most MCL but is not detected in other mature B-cell lymphomas or normal lymphoid cells. The specific expression of SOX11 in MCL suggests that it may be an important element in the development of this tumor, but its potential function is not known. Here, we show that SOX11 promotes tumor growth in a MCL-xenotransplant mouse model. Using chromatin immunoprecipitation microarray analysis combined with gene expression profiling upon SOX11 knockdown, we identify target genes and transcriptional programs regulated by SOX11 including the block of mature B-cell differentiation, modulation of cell cycle, apoptosis, and stem cell development. PAX5 emerges as one of the major SOX11 direct targets. SOX11 silencing downregulates PAX5, induces BLIMP1 expression, and promotes the shift from a mature B cell into the initial plasmacytic differentiation phenotype in both primary tumor cells and an in vitro model. Our results suggest that SOX11 contributes to tumor development by altering the terminal B-cell differentiation program of MCL and provide perspectives that may have clinical implications in the diagnosis and design of new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23321250     DOI: 10.1182/blood-2012-06-438937

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  SOX11 defines two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6.

Authors:  J Palomero; M C Vegliante; A Eguileor; M L Rodríguez; P Balsas; D Martínez; E Campo; V Amador
Journal:  Leukemia       Date:  2015-12-29       Impact factor: 11.528

2.  High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma.

Authors:  P-Y Kuo; V V Leshchenko; M J Fazzari; D Perumal; T Gellen; T He; J Iqbal; S Baumgartner-Wennerholm; L Nygren; F Zhang; W Zhang; K S Suh; A Goy; D T Yang; W-C Chan; B S Kahl; A K Verma; R D Gascoyne; E Kimby; B Sander; B H Ye; A M Melnick; S Parekh
Journal:  Oncogene       Date:  2014-03-31       Impact factor: 9.867

Review 3.  Do mantle cell lymphomas have an 'Achilles heel'?

Authors:  Nakhle Saba; Adrian Wiestner
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

4.  The role of tumor suppressor gene SOX11 in prostate cancer.

Authors:  Zhiyong Yao; Bin Sun; Quan Hong; Jingmin Yan; Dawei Mu; Jianye Li; Haibo Sheng; Heqing Guo
Journal:  Tumour Biol       Date:  2015-03-14

5.  Impact of Sox11 over-expression in Ba/F3 cells.

Authors:  Martin Lord; Gustav Arvidsson; Agata M Wasik; Birger Christensson; Anthony P Wright; Alf Grandien; Birgitta Sander
Journal:  Haematologica       Date:  2018-06-28       Impact factor: 9.941

6.  SOX11 regulates the pro-apoptosis signal pathway and predicts a favorable prognosis of mantle cell lymphoma.

Authors:  Wenjuan Yang; Yanying Wang; Zhen Yu; Zengjun Li; Gang An; Wei Liu; Rui Lv; Liping Ma; Shuhua Yi; Lugui Qiu
Journal:  Int J Hematol       Date:  2017-04-20       Impact factor: 2.490

Review 7.  Risk factors for etiology and prognosis of mantle cell lymphoma.

Authors:  Yu Wang; Shuangge Ma
Journal:  Expert Rev Hematol       Date:  2014-02-22       Impact factor: 2.929

Review 8.  Molecular Pathogenesis of Mantle Cell Lymphoma.

Authors:  Alba Navarro; Sílvia Beà; Pedro Jares; Elías Campo
Journal:  Hematol Oncol Clin North Am       Date:  2020-07-22       Impact factor: 3.722

9.  The forkhead transcription factor FOXP1 represses human plasma cell differentiation.

Authors:  Martine van Keimpema; Leonie J Grüneberg; Michal Mokry; Ruben van Boxtel; Menno C van Zelm; Paul Coffer; Steven T Pals; Marcel Spaargaren
Journal:  Blood       Date:  2015-08-19       Impact factor: 22.113

10.  Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.

Authors:  Baohua Sun; Bhavin Shah; Warren Fiskus; Jun Qi; Kimal Rajapakshe; Cristian Coarfa; Li Li; Santhana G T Devaraj; Sunil Sharma; Liang Zhang; Michael L Wang; Dyana T Saenz; Stephanie Krieger; James E Bradner; Kapil N Bhalla
Journal:  Blood       Date:  2015-08-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.